GALECTIN THERAPEUTICS INC — Director's Dealing 2014

Jan 24, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2014-01-21

Reporting Person: CALLICUTT JACK W (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-01-21	Stock Option (Right to Buy)	$13.38	A	26000	Acquired	2024-01-21	Common Stock (26000)	Direct

Footnotes

F1: 25% of the options vested upon grant date, with the remainder vesting ratably on a monthly basis over a three year period.